30 December 2023 in Photodermatology, Photoimmunology & Photomedicine
24 February 2021 in Physiological Reports
SARS‐CoV‐2 disrupts the innate immune landscape. Interferon‐lambda transcripts are increased but protein production may be blocked by viral shut‐off. However, key interferon‐stimulated antiviral gene...
8 January 2020 in American Journal of Physiology-Cell Physiology
Cystic fibrosis (CF) lung disease persists and remains life-limiting for many patients. Elevated high-mobility group box-1 protein (HMGB-1) levels and epithelial sodium channel hyperactivity (ENaC) are hallmark features of the CF lung. The objective of this study was to better understand the pathogenic role of HMGB-1 signaling and ENaC in CF airway cells. We hypothesize that HMGB-1 links airway inflammation [via signaling to the receptor for advanced glycation end products (RAGE)] and airway surface liquid dehydration (via upregulation of ENaC) in the CF lung. We calculated equivalent short-current ( Isc) and single-channel ENaC open probability ( Po) in normal and CF human small airway epithelial cells (SAEC) in the presence and absence of human HMGB-1 peptide (0.5 μg/mL). In normal SAECs, HMGB-1 increased amiloride-sensitive Isc and elevated ENaC Po from 0.15 ± 0.03 to 0.28 ± 0.04 ( P < 0.01). In CF SAECs, ENaC Po increased from 0.45 ± 0.06 to 0.73 ± 0.04 ( P < 0.01). Pretreatment with 1 μM FPS-ZM1 (a RAGE inhibitor) attenuated all HMGB-1 effects on ENaC current in normal and CF SAECs. Confocal analysis of SAECs indicates that nuclear size and HMBG-1 localization can be impacted by ENaC dysfunction. Masson’s trichrome labeling of mouse lung showed that intraperitoneally injected HMGB-1 significantly increased pulmonary fibrosis. Bronchoalveolar lavage fluid from HMGB-1-treated mice showed significant increases in IL-1β, IL-10, IL-6, IL-27, IL-17A, IFN-β, and granulocyte-macrophage colony-stimulating factor compared with vehicle-injected mice ( P < 0.05). These studies put forth a new model in which HMGB-1 signaling to RAGE plays an important role in perpetuating ENaC dysfunction and inflammation in the CF lung.
17 April 2020 in The FASEB Journal
Objective: To determine the role of the cystic fibrosis transmembrane conductance regulator (CFTR) in colon cancer development, with a focus on cell migration, EGFR signaling, and inflammation using model FHC colon epithelial cells. Background: Our clinical observations indicate that individuals with cystic fibrosis (CF) over the age of 40 are 4–8 times more likely to get colon cancer than the general population. Moreover, the likelihood of getting colon cancer increases to over 30 times the general population’s risk in CF patients who have had an organ transplant. The mechanism(s) leading to increased colon cancer in CF patients is not fully understood, but dysfunctional Cl − and Na + transport are highly implicated. Chronic inflammation has also been shown to play an important role in the development and progression of many cancers. We hypothesize that dysregulated ion transport in CF patients leads to chronic inflammation and increased incidence of colon cancer via altered epidermal growth factor receptor (EGFR) signaling. Methods: We performed scratch assays on cultured human colon epithelial cells (FHC) and measured the rate of cell migration every 24 hours for 5 days in the presence of either CFTR activating or inhibiting compounds. EGFR signaling was analyzed using standard immunohistochemical labeling techniques and commercially available reagents in similarly treated FHC cells. Results: Cells treated with 500 μM IBMX and 5 μM forskolin (CFTR activators) had significantly decreased rates of cell migration (26 μm 2 /24 hours) compared to the control group (51 μm 2 /24 hours) n=3; p<0.05. Control and colon cells treated with 500 μM IBMX and 5 μM forskolin showed low levels of EGFR labelling (restricted to cell periphery), whereas cells treated with 5 mM CFTR(inh)‐172 (CFTR inhibitor) showed more robust EGFR signal throughout the cytoplasm in 3 independent observations. Conclusion: Our data indicates that suppressed CFTR activity impacts colon epithelial cell migration and EGFR localization in FHC cells. Additional research on CFTR and EGFR signaling is needed to better understand and improve treatment options for both colon cancer and CF patients. Support or Funding Information: Funding: NIH R01 HL137033‐01 awarded to MNH.
14 May 2021 in The FASEB Journal
Objective To investigate the pathogenesis of colon cancer by determining the role of the cystic fibrosis transmembrane conductance regulator (CFTR) in regulating cell migration and epidermal growth factor receptor (EGFR) signaling. Background Individuals with cystic fibrosis (CF) over the age of 40 are 4–8 times more likely to get colon cancer than the general population. CF patients who have a history of distal intestinal obstruction syndrome and organ transplant have even higher risk of developing colon cancer. Better understanding the pathogenesis of colon cancer in CF patients may lead to improved treatments for this population. The mechanisms leading to increased colon cancer in CF patients is not fully understood, but dysfunctional Cl − transport is highly implicated. CFTR dysfunction in several tumor types has been linked to increased malignant features, such as decreased cell‐to‐cell adhesion and epithelial‐to‐mesenchymal transformation. CFTR dysfunction has also been linked to increased inflammation. We hypothesize that CFTR dysfunction in CF patients leads to colon cancer by promoting increased cell migration and altered epidermal growth factor receptor (EGFR) signaling. Methods Scratch assays were performed on fetal human colon epithelial cells (FHC) and the rate of cell migration was measured 2 days after treatment with either CFTR activating or inhibiting compounds. EGFR localization was analyzed using standard immunohistochemical labeling techniques and the fluorescence intensity of EGFR was analyzed using ImageJ. Results Colon cells treated with 500 µM IBMX and 5 µM forskolin (CFTR activators) had significantly decreased rates of cell migration (0.031 mm 2 /24 hours) compared to the control group (0.26 mm 2 /24 hours) n=6; p<0.05. Cells treated with CFTR siRNA had significantly increased rates of cell migration (0.23 mm 2 /24 hours) compared to the scramble siRNA control (0.08 mm 2 /24 hours) n=4; p<0.05. Immunohistochemistry analysis of control and colon cells treated with 500 µM IBMX and 5 µM forskolin showed low levels of EGFR labelling (restricted to cell periphery), whereas cells treated with 5 mM CFTR(inh)‐172 (CFTR inhibitor) showed more robust EGFR signal throughout the cytoplasm in 3 independent observations. Likewise, CFTR siRNA significantly increased punctate EGFR labeling in colon cells. Significance This project provides mechanistic insight into a new and critically important trend recently identified in CF patients that have increased risk for colon cancer. Our results indicate that CFTR plays an important role in regulating cell growth and migration via EGFR signaling in colon epithelia. Future studies will be aimed towards identifying novel therapeutic targets for CF and colon cancer patients to improve health outcomes.